Clinuvel Pharmaceuticals Ltd (ASX:CUV) Share Price

Company Profile

Business description
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Contact
535 Bourke Street
Level 22
MelbourneVIC3000
AUS
T: +61 396604900
https://www.clinuvel.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
100

Recommended

Despite improving prospects the shares continue to sell off.

Shane Ponraj, CFA | 08 July 2025

Fair value uneffected by suspended early-stage clinical trials.

Shane Ponraj, CFA | 18 November 2024

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Graham Hand | 02 January 2020

Index	Last price	Change	% Change
All Ordinaries	9,198.30	37.90	0.41%
CAC 40	8,286.40	5.77	0.07%
DAX 40	26,003.32	163.99	0.63%
Dow JONES (US)	53,677.14	615.19	1.16%
FTSE 100	10,831.52	75.07	0.70%
HKSE	25,213.31	97.90	-0.39%
NASDAQ	26,629.66	411.83	1.57%
Nikkei 225	64,214.48	111.16	-0.17%
NZX 50 Index	13,846.18	84.39	-0.61%
S&P 500	7,754.76	88.16	1.15%
S&P/ASX 200	9,020.10	46.10	0.51%
SSE Composite Index	3,942.09	0.70	0.02%